[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-peripheral-neuropathy-dpn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-peripheral-neuropathy-dpn":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,51,81,109,131,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100641884","ultrasound-assessment-of-sciatic-nerve-and-inferior-gluteal-artery-in-diabetic-peripheral-neuropathydpn-association-with-a-target-gene-100641884",false,"NCT07595887","Ultrasound Assessment of Sciatic Nerve and Inferior Gluteal Artery in Diabetic Peripheral Neuropathy(DPN): Association With a Target Gene","An Observational Study to Explore the Early Diagnostic Value of Ultrasonographic Sciatic Nerve Cross-Sectional Area and Inferior Gluteal Artery Blood Flow Velocity in Patients With Diabetic Peripheral Neuropathy Stratified by Severity: Integrating Bioinformatics-Based Exploration of Neuropathy Mechanisms and Correlation With a DPN Target Gene","Inclusion Criteria:\n\n* Patients diagnosed with type 2 diabetes mellitus according to the World Health Organization (WHO) diagnostic criteria; Aged between 20 and 75 years; Willing to provide written informed consent; Ability to comply with all study assessments including ultrasound examination, nerve conduction studies, and blood sampling.\n\nExclusion Criteria:\n\n* Peripheral neuropathy caused by non-diabetic conditions, including severe hepatic or renal disease, nutritional deficiencies, connective tissue diseases, or other metabolic or hereditary disorders; Nerve root compression due to cervical spondylosis or lumbar disc herniation; History of chronic alcohol abuse or long-term exposure to toxic substances (e.g., heavy metals) that may cause peripheral nerve damage; History of medication use known to affect peripheral nerve function (e.g., isoniazid, furazolidone)","ALL","20 Years","75 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","Diabetic peripheral neuropathy (DPN) is a common and serious complication of diabetes that causes numbness, pain, and weakness, often starting in the feet. Currently, there is no cure, and early diagnosis is difficult with standard tests alone. This observational study aims to find better ways to detect DPN in its early stages.\n\nThe researchers will use high-frequency ultrasound, a painless and non-invasive imaging tool, to measure two things in patients with type 2 diabetes: the cross-sectional area of the sciatic nerve (to look for swelling) and the blood flow velocity in the inferior gluteal artery (a vessel that supplies the nerve).In parallel, a bioinformatics analysis has identified a key target gene, Matrix Metalloproteinase 9(MMP9), which may play a role in nerve damage through a specific signaling pathway. The level of this protein will be measured in the patients' blood.\n\nA total of 120 participants will be grouped by the severity of their nerve damage, assessed by Toronto Clinical Scoring System (TCSS). The study will investigate whether the ultrasound measurements correlate with the clinical scores, nerve conduction studies, and the blood levels of the target protein. The ultimate goal is to combine these ultrasound structure, blood flow function, and molecular markers to build a more accurate tool for the early diagnosis and precise management of DPN, bridging the gap from early warning to mechanism-based care.",[25],"Diabetic Peripheral Neuropathy (DPN)",[27,28,29,30,31,32,33,34,35,36,37],"Diabetic Peripheral Neuropathy","Type 2 Diabetes","High-Frequency Ultrasound","Sciatic Nerve Cross-Sectional Area","Inferior Gluteal Artery Blood Flow","Matrix Metalloproteinase 9 (MMP9)","Nociceptin\u002FOrphanin FQ (N\u002FOFQ)","Toronto Clinical Scoring System (TCSS)","AMPK Signaling Pathway","Early Diagnosis","Observational Study","NOT_YET_RECRUITING","2026-06-12",{"date":41,"type":42},"2026-06-16","ACTUAL",{"date":44,"type":21},"2026-05-20",{"date":46,"type":21},"2026-07-20",{"name":48,"class":49},"Second Hospital of Shanxi Medical University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":16,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":79,"locationsCount":50},"100640143","plantar-intrinsic-muscles-exercises-and-three-dimensional-ankle-foot-exercises-comparative-effect-in-dpn-100640143","NCT07576179","Plantar Intrinsic Muscles Exercises and Three-dimensional Ankle Foot Exercises Comparative Effect in DPN","Comparative Effects of Plantar Intrinsic Muscles Exercises and 3-dimensional Ankle Foot Exercises on Balance, Gait and Fall Risk in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* The participants who scored ≥ 7 (abnormal) as per the Michigan Neuropathy Screening Instrument (MNSI)\n* Able to ambulate 10 m barefoot without using a walking aid\n* Patient reporting to have either fear of falling or experienced a fall in the previous 12 months\n* Cognitive Function on Mini-Mental State Examination is normal (MMSE score: Above 25)\n* Patients having difficulties with mobility, gait, or balance in daily life\n\nExclusion Criteria:\n\n* Presence of other neurological conditions (GBS, Paraneoplastic Neuropathy, Infectious Neuropathy, others)\n* Severe Retinopathy, a vascular complication of DM.\n* Limited Ankle and foot ROM due to fracture or contracture.\n* Presence of active plantar ulcers.\n* Recent surgeries or injuries in the foot\u002Flower limb.\n* Musculoskeletal disorders affecting gait (Osteoarthritis, Rheumatoid arthritis, Muscular dystrophy, Hip dysplasia, others)\n* Participation in another rehabilitation or training concurrently","50 Years",{"count":60,"type":21},40,"INTERVENTIONAL",[63],"NA","The aim of this study is to determine the comparative effects of plantar intrinsic muscles exercises and three-dimensional ankle foot exercises on balance, gait and fall risk in patients with diabetic peripheral neuropathy.",[25],[67,68,69,70,71],"Diabetic peripheral neuropathy","balance","gait","Plantar intrinsic muscle exercises","Three-Dimensional ankle foot exercises","RECRUITING","2026-05-04",{"date":75,"type":42},"2026-05-08",{"date":77,"type":42},"2026-04-20",{"date":46,"type":21},{"name":80,"class":49},"Riphah International University",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":61,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":50},"100607069","phase-2-a-randomized-controlled-trial-on-the-efficacy-and-safety-of-umbilical-cord-mesenchymal-stem-cell-therapy-in-subjects-with-moderate-to-severe-diabetic-peripheral-neuropathy-100607069","NCT07183761","A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic Peripheral Neuropathy","A Randomized Controlled Trial Evaluating the Efficacy and Safety of Intramuscular Human Umbilical Cord Mesenchymal Stem Cell Therapy for Subjects With Moderate to Severe Diabetic Peripheral Neuropathy","RELEASE-DPN","Inclusion Criteria:\n\n1. Males or females aged 18-80 years;\n2. Meeting the 2023 ADA diagnostic criteria for type 2 diabetes;\n3. Presence of symptoms and signs of diabetic neuropathy in lower extremities:\n\n   For symptomatic patients: At least one abnormal finding among ankle reflex, pinprick sensation, vibration sense, pressure perception, or temperature sensation, accompanied by clinical symptoms (e.g., symmetric lower limb numbness, pain, or tingling); For asymptomatic patients: At least two abnormal findings in the above five examinations;\n4. Confirmed neurophysiological dysfunction:\n\n   Reduced nerve conduction velocity (≥2 standard deviations) in at least one lower extremity nerve (common peroneal, posterior tibial, or deep peroneal nerve), with or without decreased amplitude;\n\n   Moderate to severe neuropathy severity:\n5. Toronto Clinical Scoring System (TCSS) score ≥9;\n6. Inadequate response to conventional therapy: Persistent symptoms (reduction of TCSS score \\\u003C2 points from baseline) despite ≥3 months of conventinal treatment;\n7. Capacity to understand and voluntarily complete all study procedures and interventions, with signed informed consent.\n\nExclusion Criteria:\n\n1. Non-diabetic neuropathy or pain conditions in lower limbs that may confound DPN assessment per investigator's judgment;\n2. Poorly controlled diabetes (HbA1c \\>12%);\n3. Severe hematological, hepatic, or renal dysfunction, meeting any of the following laboratory criteria:\n\n   Hematology: Neutrophils \\\u003C1.5×10⁹\u002FL, platelets \\\u003C90×10⁹\u002FL, or hemoglobin \\\u003C80 g\u002FL; Liver function: ALT or AST \\>3× upper limit of normal (ULN), or total bilirubin \\>1.5× ULN; Renal function: eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² (calculated by MDRD formula) or requiring renal replacement therapy; Creatine kinase \\>2× ULN;\n4. Known allergy to stem cells, stem cell-derived products, or components of stem cell preparations;\n5. Current use of prohibited medications within 5 half-lives prior to enrollment (may be reconsidered after ≥5 half-lives washout);\n6. Uncontrolled systemic diseases, including but not limited to: Severe uncontrolled systemic infections (bacterial, fungal, or viral); Severe autoimmune disorders; Hematological diseases; Heart failure (NYHA class ≥III);\n7. Clinically significant arrhythmia on 12-lead ECG;\n8. Conditions requiring amputation (e.g., severe diabetic foot or lower limb ulcers) that preclude local stem cell injection;\n9. Other diseases unsuitable for trial participation (e.g., active malignancy, cognitive impairment, depression, or psychiatric disorders);\n10. Participation in any interventional clinical trial within 3 months prior to screening;\n11. Pregnancy, lactation, or planning pregnancy within 2 years;\n12. Any other condition deemed by the investigator to compromise trial suitability.","18 Years","80 Years",{"count":92,"type":21},140,[94],"PHASE2","This clinical trial aims to evaluate the efficacy and safety of human umbilical cord mesenchymal stem cell (hUC-MSC) injection in the treatment of adults with moderate to severe diabetic peripheral neuropathy.\n\nResearchers will compare hUC-MSCs injection combined with conventional therapy (experimental group) to conventional therapy alone (control group) to see if hUC-MSCs work to treat diabetic peripheral neuropathy.\n\nThe experimental group will receive three injections of hUC-MSCs (on Day 0, Day 7, and Day 28) while continuing conventional therapy, whereas the control group will receive conventional therapy only. Participants will undergo regular follow-ups for checkups and tests over a 24-week period. The primary endpoint of the study is the change in the Toronto Clinical Scoring System (TCSS) score at Week 24. Safety assessments will be conducted throughout the entire study period, with extended follow-up until Week 104 to evaluate long-term safety.",[25],[27,98,99],"Mesenchymal Stem Cell Transplantation","Randomized Controlled Trial","2026-04-21",{"date":102,"type":42},"2026-04-23",{"date":104,"type":42},"2025-10-01",{"date":106,"type":21},"2028-08-30",{"name":108,"class":49},"Min Long",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":89,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":61,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100635364","effect-of-low-frequency-electroacupuncture-on-diabetic-peripheral-neuropathy-100635364","NCT07551726","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy","Effect of Low-Frequency Electroacupuncture on Diabetic Peripheral Neuropathy: Study Protocol for a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- 1.Aged 18-70 years, with no restriction on disease duration or sex. 2.Met the diagnostic criteria for DPN, evidenced by: decreased NCV on lower-limb electroneurography, and\u002For persistent pain and\u002For sensory abnormalities in the limbs (at least in both lower limbs), with diminished ankle reflex (unilateral or bilateral) and reduced vibration sense, and a Toronto Clinical Scoring System (TCSS) score ≥ 6.\n\n3.Able to communicate effectively. 4.No severe systemic medical conditions (e.g., cardiac, cerebral, hepatic, or renal disorders), severe psychiatric illnesses, or cognitive impairment.\n\n5.Mentally competent, voluntarily agree to participate in the study, and provide written informed consent.\n\nExclusion Criteria:\n\n* 1.Peripheral neuropathy due to other etiologies (e.g., hypothyroidism, alcohol, medications, hereditary causes), presence of limb ulcers or gangrene, or a history of skin ulceration or poorly healing lesions.\n\n  2.Severe comorbid conditions, including renal, cardiovascular, cerebrovascular, pulmonary, or hepatic diseases, infectious diseases, malignancies, or severe psychiatric disorders.\n\n  3.History of knee\u002Fhip replacement surgery or lower limb fracture within the past 3 months, or any other condition that could interfere with the assessment of neuropathy.\n\n  4.Received acupuncture or moxibustion treatment specifically for DPN within the past 3 months.\n\n  5.Concurrent participation in another interventional clinical trial. 6.Women who are planning pregnancy, are pregnant, or are lactating. 7.Unwillingness to be randomized to either the waitlist (WL) or EA group. 8.Chronic abuse of opioids, analgesics, illicit drugs, or alcohol.","70 Years",{"count":118,"type":21},92,[63],"Diabetic peripheral neuropathy (DPN) is a common and disabling complication of diabetes. Many patients experience pain, numbness, and impaired quality of life, while currently available treatments may have limited benefit or cause adverse effects. Electroacupuncture (EA) may provide a safe, non-pharmacological treatment option, but further clinical evidence is needed.\n\nThe purpose of this study is to evaluate the efficacy and potential mechanisms of low-frequency (2 Hz) electroacupuncture in patients with DPN. In this prospective, randomized, sham-controlled trial, participants will be assigned to either a verum 2 Hz EA group or a sham EA group. The study will assess nerve conduction velocity, pain intensity, serum neurotrophic factors and inflammatory cytokines, and quality of life.\n\nThis study is intended to provide clinical evidence on the use of low-frequency EA for DPN and to examine whether its effects are related to neurotrophic and inflammatory pathways.",[25,122],"Electroacupuncture",{"date":124,"type":42},"2026-04-27",{"date":126,"type":21},"2026-04-26",{"date":128,"type":21},"2027-12-31",{"name":130,"class":49},"The First Affiliated Hospital of Zhejiang Chinese Medical University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":16,"minAge":89,"maxAge":90,"enrollmentInfo":138,"targetDuration":140,"studyType":22,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":50},"100632803","study-on-serum-transcriptomics-and-metabolomics-in-patients-with-diabetic-peripheral-neuropathy-100632803","NCT07518433","Study on Serum Transcriptomics and Metabolomics in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Patients diagnosed with diabetes mellitus (type 1 or type 2)\n* For the diabetic peripheral neuropathy (DPN) group: meet diagnostic criteria for painful diabetic peripheral neuropathy (P-DPN), defined as persistent pain and\u002For paresthesia in both lower limbs, with at least one objective sign of neuropathy (reduced ankle reflex, reduced vibration perception, or abnormal nerve conduction velocity when available), and a DN4 score ≥ 4\n* For the diabetic control (DC) group: patients with diabetes mellitus but no evidence of peripheral neuropathy\n* For the healthy control (HC) group: healthy volunteers without diabetes or neuropathy, matched for sex and age\n* Aged between 18 and 80 years (inclusive)\n* Able to perform activities of daily living independently and cooperate with study procedures\n* No severe cardiac, cerebral, hepatic, renal, or other systemic diseases, and no severe mental illness or cognitive impairment\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Peripheral neuropathy caused by factors other than diabetes, including but not limited to hypothyroidism, alcohol abuse, medications, genetic disorders, or other systemic diseases\n* Presence of limb ulcers, gangrene, or a history of skin ulceration or non-healing wounds\n* Acute diabetic complications such as diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, or severe infections within the past 3 months\n* Severe hepatic or renal impairment, or severe cardiovascular or cerebrovascular diseases (e.g., unstable angina, myocardial infarction, multiple cerebral infarctions, cerebral hemorrhage)\n* Scars or hyperpigmentation at the testing site that may interfere with accurate measurements\n* Pregnancy, breastfeeding, or planned pregnancy during the study period\n* Participation in another interventional clinical trial within 3 months prior to screening\n* For the diabetic control (DC) group: presence of peripheral neuropathy\n* For the healthy control (HC) group: history of diabetes mellitus, peripheral neuropathy, or use of medications affecting neurological function",true,{"count":139,"type":21},90,"90 Months","This part of the study enrolled 30 sex- and age-matched healthy controls, 30 diabetic patients without peripheral neuropathy, and 30 patients with diabetic peripheral neuropathy (DPN). Blood samples were collected from the participants, and serum was isolated for transcriptomics and untargeted metabolomics analysis using liquid chromatography-mass spectrometry (LC-MS) to characterize the metabolic profile of DPN. Through differential comparison analysis, serum biomarkers associated with DPN were identified and further correlated with clinical parameters. This approach aims to establish early diagnostic markers for DPN and provide scientific evidence for understanding the complex mechanisms underlying DPN, thereby offering new insights into potential therapeutic strategies.",[25,143],"Pain",[27,143],"2026-04-06",{"date":147,"type":42},"2026-04-08",{"date":149,"type":21},"2026-03-20",{"date":151,"type":21},"2027-06-30",{"name":153,"class":154},"Zhejiang Chinese Medical University","OTHER_GOV",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":162,"maxAge":90,"enrollmentInfo":163,"targetDuration":4,"studyType":61,"phases":165,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":50},"100598982","tai-chi-vs-modified-otago-exercises-for-pain-balance-and-motor-function-in-diabetic-peripheral-neuropathy-100598982","NCT07078565","Tai Chi vs. Modified-Otago Exercises for Pain, Balance, and Motor Function in Diabetic Peripheral Neuropathy","Comparative Effects of Tai Chi Versus Modified-Otago Exercises On Pain, Balance And Motor Function In Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Both genders are aged 40-80 years\n* Patient having Types ii diabetes with Minimum of 5 years since diabetes diagnosis\n* Patients experiencing chronic pain for at least 6 months and level ≥ 3 on NPRS.\n* Patient having ≥ 6 score on Toronto Clinical Neuropathy Scoring System for diabetic neuropathy\n\nExclusion Criteria:\n\n* Non-ambulatory patients\n* Patients with ulceration\u002Finfection of feet, medical\u002Fsurgical conditions\n* Patients suffering from stroke, parkinson's disease, or multiple sclerosis","40 Years",{"count":164,"type":21},36,[63],"his randomized clinical trial evaluates the comparative effectiveness of Tai Chi and Modified-Otago exercise programs on pain reduction, balance improvement, and motor function in patients diagnosed with diabetic peripheral neuropathy (DPN). DPN is a common complication of Type 2 Diabetes Mellitus that significantly impairs quality of life through chronic pain, balance deficits, and decreased functional mobility. While pharmacological treatments are commonly used, they often result in adverse side effects, creating a growing need for non-pharmacological interventions like therapeutic exercises.\n\nTai Chi, a traditional Chinese exercise combining slow movements and mental focus, has shown benefits in improving mobility and reducing fall risks in chronic disease populations. The Modified-Otago program, originally developed to prevent falls in the elderly, emphasizes strength and balance training through structured exercise routines.\n\nA total of 36 participants (aged 40-80 years) with at least a 5-year history of Type 2 diabetes and a minimum pain score of ≥3 on the Numeric Pain Rating Scale (NPRS) will be recruited. Participants will be randomly allocated to either the Tai Chi group or the Modified-Otago group. Both groups will receive 24 sessions over an 8-week period (3 sessions per week), along with baseline interventions such as heating pad application, TENS, and warm-up\u002Fcool-down routines.\n\nPrimary outcome measures include NPRS for pain, the Berg Balance Scale (BBS) for balance, and the Dynamic Gait Index (DGI) for motor function. Assessments will be conducted at baseline, post-intervention, and two weeks post-treatment. Data will be analyzed using SPSS version 26 to determine within-group and between-group differences.\n\nThis study aims to inform clinicians about effective exercise strategies for improving physical function in patients with DPN and potentially establish evidence-based rehabilitation protocols.",[25,168],"Type 2 Diabetes Mellitus (T2DM)",[27,170,171,172],"Tai Chi","Modified-Otago Exercises","Balance Training","2025-07-21",{"date":175,"type":42},"2025-07-22",{"date":177,"type":42},"2025-01-25",{"date":179,"type":21},"2025-12-30",{"name":80,"class":49}]